Furthermore, because an NF-κB inhibitor attenuated CXCL1-induced cell invasion in CXCR2 positive cells (Figure 5D and 6G), our results suggest that the CXCL1-CXCR2 axis may accelerate cancer progression by potentiating NF-κB signaling. Here, NFKB1 is linked to cancer.